Invictus MD (TSXV:IMH) announced today that it has engaged Canaccord Genuity Corp. and Eventus Capital Corp., as co-lead underwriters and joint-bookrunners, on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought deal private placement basis, subject to adjustment
Invictus MD (TSXV:IMH) is pleased to announce that AB Laboratories Inc. (“AB Labs”), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), will provide their unique products in Canopy Growth Corporation’s (TSX:WEED) (“Canopy Growth”) curated CraftGrow line on Tweed Main Street’s online store, that brings high
Invictus MD (TSXV:IMH) is pleased to report that Future Harvest Development Ltd. (“Future Harvest”), of which Invictus MD currently owns 82.5%, has generated $1.787 million in revenue for the 9 months ending March 31, 2017, with a gross margin of $907,864, representing a 50.8% gross margin compared to the same
Inovio Pharmaceuticals announced its Ebola vaccine showed promising preliminary results from an expanded Phase I study.
Acreage Pharms Ltd., which Invictus MD (CNX:IMH). has the option to now acquire 100 per cent of and expects to exercise in short order, has begun its new cultivation cycle, having received its licence to cultivate under the access to cannabis for medical purposes regulations (ACMPR); Acreage is firmly committed
Invictus MD (CNX:IMH), Canada’s cannabis company, is pleased to announce that its common shares will be delisted from the Canadian Securities Exchange after the close of trading on March 30, 2017 and will be listed on the TSX Venture Exchange (“TSXV”) commencing at the open of trading on March 31,
Invictus MD Strategies Corp. CNX:IMH) is providing an update of its production capability in preparation for the recreational cannabis market.
Marijuana could be legal in Canada by July 1, 2018; according to CBC News, it has learned that the legislation will be announced during the week of April 10 and will
Invictus MD (CNX:IMH) is pleased to announce it has received conditional approval to list its common shares for trading on the TSX Venture Exchange.
Invictus MD (CNX:IMH) – Mr. Kveton is a highly effective, strategic and pragmatic international executive and investment professional, with broad experience operating in both Fortune 500 and start-up environments. He has a proven record in generating top-line growth by executing cross-border merger and acquisition deals and transformations to a high
Cerulean Pharma leads the list of last week’s life science gainers on the NASDAQ, followed by Catalyst Pharmaceutical, Neovasc, Arbutus Biopharma and Tetraphase.
The Genetic Non-Discrimination Act is one step away to being a law in Canada, and will potentially impact the life science sector.